Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis
Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
People with psoriasis have significantly higher rates of obesity, diabetes, heart failure and
high blood pressure than the general public. The purpose of this study is to determine how
substances produced in the fat (inflammatory markers) relate to the risk of heart disease in
people with the metabolic syndrome and psoriasis. People with metabolic syndrome have insulin
resistance, increased waist size, high blood pressure, or high cholesterol.